Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Feb 9;13:759. doi: 10.1038/s41467-022-28407-4

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 7 — a WT and CCR2^−/− mice were treated with PBS or WGP and 7 days later were implanted with orthotopic KPC pancreatic tumor cells. Tumor weight at day 21 is reported. (WT PBS n = 5, WT WGP n = 6, CCR2 PBS n = 6, CCR2^−/− WGP n = 6). **p = 0.0027 (WT PBS vs WT WGP), *p = 0.0118 (WT WGP vs CCR2^−/− PBS), **p = 0.0034 (WT WGP vs CCR2^−/− WGP). b Sorted CCR2⁺ and CCR2⁻ pancreatic CD11b⁺ cells from WGP-trained mice were admixed with KPC cells and implanted orthotopically. Tumor size was evaluated 21 days later (CCR2⁺ n = 5, CCR2⁻ n = 5). *p = 0.0247. c t-SNE plots generated by CyTOF analysis of the admix tumors from b. Clusters showing significant differences between groups are indicated by the circles. Total data (left) and representative t-SNE plots of each group are shown. d Summarized percent of CD8⁺ and CD11b⁺ cells in admix tumors (PBS n = 4, WGP n = 3). *p = 0.01, **p = 0.007. e The ratio of CD8⁺:CD11b⁺ cells in admix tumors (PBS n = 4, WGP n = 3). *p = 0.0474. f Expression of PD-L1 on KPC tumor cells, CD11b⁺ and F4/80⁺ cells in a KPC tumor 21 days after implantation (KPC n = 5, CD11b⁺ n = 6, F4/80⁺ n = 6). g Experimental schema of WGP and anti-PD-L1 therapy. Mice (n = 5) were treated with PBS or WGP and 7 days later were implanted with orthotopic KPC pancreatic tumors. On days 3, 7, and 11 post-implantation, mice were given anti-PD-L1 mAb or anti-rat IgG2b mAb isotype control. Survival was monitored. **p = 0.0018 (WGP vs PBS or PD-L1), **p = 0.0021 (WGP vs WGP + PD-L1). h Experimental schema of WGP used in the therapeutic setting. Mice were implanted with orthotopic KPC pancreatic tumors and were given WGP once mice had recovered from the surgery at day 4, and 1 week later on day 11. *p = 0.0163. Data were represented as mean ± SEM. A one-way ANOVA with multiple comparisons was used for a and an unpaired, two-tailed student’s t-test was used for b, d, and e. Log-rank test was used for g and h. ns not significant. Each sample represents a biologically independent animal obtained over a single independent experiment which was repeated at least twice for verification of results.